Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
- Study type
- Review article
- Study name
- SNO/EANO Glioblastoma 2025
- Design
- Consensus review by SNO and EANO
- Source
- Neuro-Oncology · 2025
In plain words
Glioblastoma is the most common malignant tumour that starts in the brain. This paper, written by two specialist neuro-oncology societies, reviews how the disease is currently treated. It also introduces new treatments being studied, such as immunotherapy, virus-based treatments and targeted molecular treatments. Treatment decisions should always be made with the care team and your treating doctor.
Study population
This paper is a consensus review and enrolled no specific patients. Its subject is adult glioblastoma, which under the 2021 World Health Organization classification is restricted to tumours without an IDH mutation (IDH-wildtype).
Endpoints
This paper is a consensus review and has no defined primary or secondary endpoints. The abstract covers current patient management, novel therapies, current challenges and future research directions.
Safety and side effects
The abstract gives no information on adverse events. Details are available in the full text.
Clinical significance and place in guidelines
This updated consensus review from SNO and EANO provides a framework for the current management of glioblastoma based on the 2021 World Health Organization classification (restricting glioblastoma to IDH-wildtype tumours). This classification allows more homogeneous patient populations to be enrolled in trials. The abstract does not mention specific clinical recommendations or levels of evidence; for treatment details and its status in clinical guidelines, the full text and authoritative guidelines should be consulted.
Limitations
This card is based only on the abstract; details of the recommendations, levels of evidence, treatment regimens and data on novel therapies are in the full text. The abstract also provides no quantitative results.
This summary was prepared by the editorial team from the published paper; the original paper is the final reference. Read the original abstract on PubMed.